3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
24
Terminated
5
Recruiting
2
Unknown
1
Not yet recruiting
1
No longer available
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms
1
Interventions
Temozolomide
66
Radiotherapy
52
Carboplatin
25
Bevacizumab
21
Cisplatin
19
Radiosurgery
18
Vincristine
17
Etoposide
17
Cyclophosphamide
17
Surgical Procedures, Operative
13
Magnetic Resonance Spectroscopy
13
Chemotherapy, Adjuvant
11
Melphalan
10
Lomustine
10
Drug Therapy
10
Filgrastim
9
Erlotinib Hydrochloride
9
apatinib
8
Pemetrexed
8
3-Iodobenzylguanidine
8
anlotinib
7
Radiation
7
Peripheral Blood Stem Cell Transplantation
7
Methotrexate
7
Thiotepa
6
Isotretinoin
6
Irinotecan
6
Ifosfamide
6
Doxorubicin
6
Carmustine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Vorinostat
×
CNS
×
Clear all
NCT03561259
2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2
Unknown
60 enrolled